JP2019519489A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019519489A5 JP2019519489A5 JP2018558275A JP2018558275A JP2019519489A5 JP 2019519489 A5 JP2019519489 A5 JP 2019519489A5 JP 2018558275 A JP2018558275 A JP 2018558275A JP 2018558275 A JP2018558275 A JP 2018558275A JP 2019519489 A5 JP2019519489 A5 JP 2019519489A5
- Authority
- JP
- Japan
- Prior art keywords
- dry powder
- particles
- dry
- powder inhalation
- inhalation composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000843 powder Substances 0.000 claims description 48
- 239000000203 mixture Substances 0.000 claims description 40
- 239000002245 particle Substances 0.000 claims description 38
- 229960005032 treprostinil Drugs 0.000 claims description 19
- PAJMKGZZBBTTOY-ZFORQUDYSA-N treprostinil Chemical compound C1=CC=C(OCC(O)=O)C2=C1C[C@@H]1[C@@H](CC[C@@H](O)CCCCC)[C@H](O)C[C@@H]1C2 PAJMKGZZBBTTOY-ZFORQUDYSA-N 0.000 claims description 19
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 16
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 16
- 238000000034 method Methods 0.000 claims description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 12
- 206010064911 Pulmonary arterial hypertension Diseases 0.000 claims description 11
- 239000004395 L-leucine Substances 0.000 claims description 8
- 235000019454 L-leucine Nutrition 0.000 claims description 8
- 229960003136 leucine Drugs 0.000 claims description 8
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims description 8
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 8
- 229920000053 polysorbate 80 Polymers 0.000 claims description 8
- 229940068968 polysorbate 80 Drugs 0.000 claims description 8
- 239000011780 sodium chloride Substances 0.000 claims description 8
- 239000002775 capsule Substances 0.000 claims description 7
- DPVHGFAJLZWDOC-PVXXTIHASA-N (2r,3s,4s,5r,6r)-2-(hydroxymethyl)-6-[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxane-3,4,5-triol;dihydrate Chemical compound O.O.O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 DPVHGFAJLZWDOC-PVXXTIHASA-N 0.000 claims description 6
- 229960000999 sodium citrate dihydrate Drugs 0.000 claims description 6
- 229940074409 trehalose dihydrate Drugs 0.000 claims description 6
- IQKAWAUTOKVMLE-ZSESPEEFSA-M treprostinil sodium Chemical compound [Na+].C1=CC=C(OCC([O-])=O)C2=C1C[C@@H]1[C@@H](CC[C@@H](O)CCCCC)[C@H](O)C[C@@H]1C2 IQKAWAUTOKVMLE-ZSESPEEFSA-M 0.000 claims description 6
- 229960001726 treprostinil sodium Drugs 0.000 claims description 6
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 claims description 6
- 239000006172 buffering agent Substances 0.000 claims description 4
- 239000003002 pH adjusting agent Substances 0.000 claims description 4
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims description 2
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims description 2
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 238000001035 drying Methods 0.000 claims description 2
- 239000003906 humectant Substances 0.000 claims description 2
- 210000004072 lung Anatomy 0.000 claims description 2
- 239000003607 modifier Substances 0.000 claims description 2
- 238000000465 moulding Methods 0.000 claims description 2
- 229960002668 sodium chloride Drugs 0.000 claims description 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims description 2
- 239000001509 sodium citrate Substances 0.000 claims description 2
- 239000007787 solid Substances 0.000 claims description 2
- 229940074410 trehalose Drugs 0.000 claims description 2
- 239000000080 wetting agent Substances 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims 1
- 229940112141 dry powder inhaler Drugs 0.000 description 4
- 238000002664 inhalation therapy Methods 0.000 description 2
- 239000000945 filler Substances 0.000 description 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023031081A JP2023071844A (ja) | 2016-05-05 | 2023-03-01 | 肺高血圧症を治療するための乾燥粉末トレプロスチニル |
| JP2025077118A JP2025118785A (ja) | 2016-05-05 | 2025-05-07 | 肺高血圧症を治療するための乾燥粉末トレプロスチニル |
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662332013P | 2016-05-05 | 2016-05-05 | |
| US62/332,013 | 2016-05-05 | ||
| US201662404960P | 2016-10-06 | 2016-10-06 | |
| US62/404,960 | 2016-10-06 | ||
| US201662440078P | 2016-12-29 | 2016-12-29 | |
| US62/440,078 | 2016-12-29 | ||
| US201762472204P | 2017-03-16 | 2017-03-16 | |
| US62/472,204 | 2017-03-16 | ||
| PCT/US2017/031301 WO2017192993A1 (en) | 2016-05-05 | 2017-05-05 | Dry powder treprostinil for the treatment of pulmonary hypertension |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023031081A Division JP2023071844A (ja) | 2016-05-05 | 2023-03-01 | 肺高血圧症を治療するための乾燥粉末トレプロスチニル |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019519489A JP2019519489A (ja) | 2019-07-11 |
| JP2019519489A5 true JP2019519489A5 (cg-RX-API-DMAC7.html) | 2020-06-18 |
Family
ID=60203775
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018558275A Pending JP2019519489A (ja) | 2016-05-05 | 2017-05-05 | 肺高血圧症を治療するための乾燥粉末トレプロスチニル |
| JP2023031081A Pending JP2023071844A (ja) | 2016-05-05 | 2023-03-01 | 肺高血圧症を治療するための乾燥粉末トレプロスチニル |
| JP2025077118A Pending JP2025118785A (ja) | 2016-05-05 | 2025-05-07 | 肺高血圧症を治療するための乾燥粉末トレプロスチニル |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023031081A Pending JP2023071844A (ja) | 2016-05-05 | 2023-03-01 | 肺高血圧症を治療するための乾燥粉末トレプロスチニル |
| JP2025077118A Pending JP2025118785A (ja) | 2016-05-05 | 2025-05-07 | 肺高血圧症を治療するための乾燥粉末トレプロスチニル |
Country Status (7)
| Country | Link |
|---|---|
| US (9) | US10898494B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3452170A4 (cg-RX-API-DMAC7.html) |
| JP (3) | JP2019519489A (cg-RX-API-DMAC7.html) |
| AU (3) | AU2017261317A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3023257A1 (cg-RX-API-DMAC7.html) |
| IL (3) | IL319790A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2017192993A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2010259943C1 (en) | 2009-06-12 | 2016-03-03 | Mannkind Corporation | Diketopiperazine microparticles with defined specific surface areas |
| EP2861296A1 (en) * | 2012-06-15 | 2015-04-22 | Case Western Reserve University | Therapy delivery devices and methods for non-damaging neural tissue conduction block |
| BR112015023168B1 (pt) | 2013-03-15 | 2021-08-10 | Mannkind Corporation | Composição de 3,6-bis(n-fumaril-4-aminobutil)-2,5-dicetopiperazina cristalina, método de produção de partículas de 3,6-bis(n-fumaril-4-aminobutil)-2,5-dicetopiperazina e uso de uma composição de dicetopiperazina cristalina |
| BR122019026637B1 (pt) | 2013-07-18 | 2023-09-26 | Mannkind Corporation | Formulações farmacêuticas de pó seco e método para a fabricação de uma formulação de pó seco |
| US9469600B2 (en) | 2013-10-25 | 2016-10-18 | Insmed Incorporated | Prostacyclin compounds, compositions and methods of use thereof |
| US10343979B2 (en) | 2014-11-18 | 2019-07-09 | Insmed Incorporated | Methods of manufacturing treprostinil and treprostinil derivative prodrugs |
| US20190321290A1 (en) * | 2016-01-29 | 2019-10-24 | Mannkind Corporation | Composition and method for inhalation |
| EP3452170A4 (en) | 2016-05-05 | 2020-04-01 | Liquidia Technologies, Inc. | TREPROSTINIL IN POWDER FORM FOR TREATING PULMONAL HYPERTENSION |
| SG11202011045VA (en) * | 2018-05-07 | 2020-12-30 | Pharmosa Biopharm Inc | Pharmaceutical composition for controlled release of treprostinil |
| CA3102967A1 (en) * | 2018-06-07 | 2019-12-12 | Mannkind Corporation | Composition and method for inhalation |
| CN119632930A (zh) | 2019-04-29 | 2025-03-18 | 英斯梅德股份有限公司 | 曲前列素前药的干粉组合物及其使用方法 |
| CN114401716A (zh) | 2019-07-22 | 2022-04-26 | 纳诺米有限公司 | 持续释放的曲前列环素-化合物微粒组合物 |
| IL296567A (en) | 2020-04-17 | 2022-11-01 | United Therapeutics Corp | Terfostinil for use in the treatment of interstitial lung disease |
| CN116437906B (zh) * | 2020-10-28 | 2026-07-03 | 英斯梅德股份有限公司 | 曲前列环素前药的干粉组合物和其使用方法 |
| CA3235985A1 (en) * | 2021-10-27 | 2023-05-04 | Mannkind Corporation | Methods and compositions for treating pulmonary hypertension |
| WO2023154705A1 (en) * | 2022-02-08 | 2023-08-17 | United Therapeutics Corporation | Treprostinil iloprost combination therapy |
| EP4516297A4 (en) | 2022-04-29 | 2026-02-25 | Zhaoke pharmaceutical guangzhou co ltd | Treprostinil Gentle Inhalation Mist |
| WO2025174856A1 (en) * | 2024-02-12 | 2025-08-21 | Mannkind Corporation | Process for making a composition for pulmonary inhalation |
Family Cites Families (84)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS56122328A (en) | 1980-02-29 | 1981-09-25 | Sumitomo Chem Co Ltd | Crystalline amine salt of methanoplastocyclin, its preparation and purifying method |
| US4306075A (en) | 1980-03-28 | 1981-12-15 | The Upjohn Company | Composition and process |
| GB8814438D0 (en) | 1988-06-17 | 1988-07-20 | Wellcome Found | Compounds for use in medicine |
| US5441060A (en) * | 1993-02-08 | 1995-08-15 | Duke University | Dry powder delivery system |
| CH687615A5 (de) * | 1994-09-07 | 1997-01-15 | R W Johnson Pharmaceutical Res | Tropen-Verpackung. |
| US6503480B1 (en) | 1997-05-23 | 2003-01-07 | Massachusetts Institute Of Technology | Aerodynamically light particles for pulmonary drug delivery |
| US5874064A (en) | 1996-05-24 | 1999-02-23 | Massachusetts Institute Of Technology | Aerodynamically light particles for pulmonary drug delivery |
| US6441245B1 (en) | 1997-10-24 | 2002-08-27 | United Therapeutics Corporation | Process for stereoselective synthesis of prostacyclin derivatives |
| US20030118567A1 (en) | 1999-03-26 | 2003-06-26 | Stewart Duncan John | Cell-based therapy for the pulmonary system |
| US6521212B1 (en) * | 1999-03-18 | 2003-02-18 | United Therapeutics Corporation | Method for treating peripheral vascular disease by administering benzindene prostaglandins by inhalation |
| US6858199B1 (en) | 2000-06-09 | 2005-02-22 | Advanced Inhalation Research, Inc. | High efficient delivery of a large therapeutic mass aerosol |
| US7305986B1 (en) * | 1999-07-23 | 2007-12-11 | Mannkind Corporation | Unit dose capsules for use in a dry powder inhaler |
| US6242482B1 (en) | 2000-06-05 | 2001-06-05 | United Therapeutics Corporation | Prostaglandin compounds and derivatives thereof, compositions containing the same and method of using the same for the treatment of congestive heart failure |
| EG24184A (en) * | 2001-06-15 | 2008-10-08 | Otsuka Pharma Co Ltd | Dry powder inhalation system for transpulmonary |
| US6889690B2 (en) * | 2002-05-10 | 2005-05-10 | Oriel Therapeutics, Inc. | Dry powder inhalers, related blister devices, and associated methods of dispensing dry powder substances and fabricating blister packages |
| GB0219511D0 (en) * | 2002-08-21 | 2002-10-02 | Norton Healthcare Ltd | Method of preparing dry powder inhalation compositions |
| CN102697790A (zh) | 2003-05-22 | 2012-10-03 | 联合治疗公司 | 化合物和释放前列环素类似物的方法 |
| AU2004249166B2 (en) | 2003-06-13 | 2008-10-09 | Alkermes, Inc. | Low dose pharmaceutical powders for inhalation |
| US20040265238A1 (en) | 2003-06-27 | 2004-12-30 | Imtiaz Chaudry | Inhalable formulations for treating pulmonary hypertension and methods of using same |
| ATE551383T1 (de) | 2003-09-23 | 2012-04-15 | Univ North Carolina | Photohärtbare perfluorpolyether zur verwendung als neue werkstoffe in mikrofluidischen vorrichtungen |
| US7199157B2 (en) | 2003-12-16 | 2007-04-03 | United Therapeutics Corporation | Use of treprostinil to improve kidney functions |
| CN1917866B (zh) | 2003-12-16 | 2010-12-15 | 联合治疗公司 | 曲前列环素或它的衍生物,或其药学上可接受的盐在制备治疗和预防缺血性损害的药物中的用途 |
| WO2005101466A2 (en) | 2003-12-19 | 2005-10-27 | The University Of North Carolina At Chapel Hill | Methods for fabricating isolated micro- and nano- structures using soft or imprint lithography |
| US9214590B2 (en) | 2003-12-19 | 2015-12-15 | The University Of North Carolina At Chapel Hill | High fidelity nano-structures and arrays for photovoltaics and methods of making the same |
| WO2007021762A2 (en) | 2005-08-09 | 2007-02-22 | The University Of North Carolina At Chapel Hill | Methods and materials for fabricating microfluidic devices |
| DE602005020269D1 (de) | 2004-04-12 | 2010-05-12 | United Therapeutics Corp | Verwendung von treprostinil zur behandlung von neuropathischen diabetischen fussgeschwüren |
| CA2574958A1 (en) | 2004-07-26 | 2006-02-09 | Cotherix, Inc. | Treatment of pulmonary hypertension by inhaled iloprost with a microparticle formulation |
| HUE025151T2 (en) | 2004-08-23 | 2016-01-28 | Mannkind Corp | Diceto-piperazine salts for drug delivery |
| WO2007133808A2 (en) | 2006-05-15 | 2007-11-22 | Liquidia Technologies, Inc. | Nano-particles for cosmetic applications |
| CA2654492C (en) | 2006-05-15 | 2017-06-27 | United Therapeutics Corporation | Treprostinil administration using a metered dose inhaler |
| CA2655477C (en) | 2006-06-16 | 2015-05-05 | Cipla Limited | Vibration assisted release of encapsulated inhalable powder |
| US20090036465A1 (en) | 2006-10-18 | 2009-02-05 | United Therapeutics Corporation | Combination therapy for pulmonary arterial hypertension |
| US8128393B2 (en) | 2006-12-04 | 2012-03-06 | Liquidia Technologies, Inc. | Methods and materials for fabricating laminate nanomolds and nanoparticles therefrom |
| WO2009049299A1 (en) | 2007-10-12 | 2009-04-16 | Liquidia Technologies, Inc. | System and method for producing particles and patterned films |
| WO2009078965A1 (en) | 2007-12-17 | 2009-06-25 | United Therapeutics Corporation | An improved process to prepare treprostinil, the active ingredient in remodulin |
| US20110151015A1 (en) | 2008-03-04 | 2011-06-23 | Liquikia Technologies, Inc. | Immunomodulator particles and methods of treating |
| EP2257326A2 (en) * | 2008-03-21 | 2010-12-08 | Novartis AG | Powder dispersion apparatus |
| JP6219016B2 (ja) | 2008-05-08 | 2017-10-25 | ユナイテッド セラピューティクス コーポレーション | トレプロスチニル一水和物 |
| WO2009150136A1 (de) | 2008-06-09 | 2009-12-17 | Boehringer Ingelheim International Gmbh | Neue einbettungspartikel für die inhalation |
| WO2009152160A1 (en) * | 2008-06-10 | 2009-12-17 | Gilead Sciences, Inc. | Inhaled carbaprostacyclin and prostacyclin prodrugs for the treatment of pulmonary arterial hypertension |
| EP2330893A4 (en) | 2008-09-25 | 2013-01-09 | Aradigm Corp | DEEP PULMONARY ADMINISTRATION OF TREPROSTINIL |
| CN104162947B (zh) | 2008-12-05 | 2017-04-12 | 流体科技公司 | 产生有图案的材料的方法 |
| AU2010259943C1 (en) | 2009-06-12 | 2016-03-03 | Mannkind Corporation | Diketopiperazine microparticles with defined specific surface areas |
| US20120114554A1 (en) | 2009-07-13 | 2012-05-10 | Liquidia Technologies, Inc. | Engineered Aerosol Particles, And Associated Methods |
| AU2010280684B2 (en) | 2009-08-07 | 2016-07-28 | Scipharm Sarl | Composition for the treatment of cystic fibrosis |
| EP2338520A1 (de) | 2009-12-21 | 2011-06-29 | Ludwig Maximilians Universität | Konjugat mit Zielfindungsligand und dessen Verwendung |
| US20130209564A1 (en) | 2010-02-22 | 2013-08-15 | Shyam M. Rele | Polysaccharide Particle Vaccines |
| CN102869402A (zh) * | 2010-04-23 | 2013-01-09 | 3M创新有限公司 | 干粉吸入器组件和容器 |
| CA2726599C (en) | 2010-12-30 | 2017-07-25 | Alphora Research Inc. | Process for treprostinil salt preparation |
| PL2663313T3 (pl) | 2011-01-13 | 2019-01-31 | SciPharm S.à r.l. | Sposób zwiększania wszczepiania hematopoetycznych komórek macierzystych |
| JP5780775B2 (ja) | 2011-02-18 | 2015-09-16 | 株式会社Lttバイオファーマ | プロスタグランジンi2誘導体を含有するナノ粒子 |
| EP2526926A1 (de) | 2011-05-25 | 2012-11-28 | Justus-Liebig-Universität Gießen | Biokompatible Nanopolymerpartikel mit Wirkstoffen für die pulmonale Applikation |
| AU2012296953B2 (en) | 2011-08-12 | 2016-10-20 | Ascendis Pharma A/S | Sustained release composition of prostacyclin |
| CA2850484C (en) | 2011-09-30 | 2021-01-26 | Bluebird Bio, Inc. | Compounds for improved viral transduction |
| AU2012328524B2 (en) * | 2011-10-28 | 2017-05-18 | Excelse Bio, Inc. | Protein formulations containing amino acids |
| US9554968B2 (en) | 2013-03-11 | 2017-01-31 | Sio2 Medical Products, Inc. | Trilayer coated pharmaceutical packaging |
| CN107875127A (zh) | 2012-02-28 | 2018-04-06 | 艾塞尤提卡控股公司 | 可吸入药物组合物 |
| US20150136130A1 (en) * | 2012-02-29 | 2015-05-21 | Pulmatrix, Inc. | Inhalable dry powders |
| US10071209B2 (en) | 2012-03-15 | 2018-09-11 | Steadymed Ltd. | Enhanced infusion-site pain-reduction for drug-delivery devices |
| CN104684561A (zh) | 2012-08-01 | 2015-06-03 | 联合治疗公司 | 利用间充质干细胞的肺动脉高血压的治疗 |
| WO2014085813A1 (en) | 2012-11-30 | 2014-06-05 | Insmed Incorporated | Prostacylin compositions and methods for using the same |
| US9505737B2 (en) * | 2013-01-11 | 2016-11-29 | Corsair Pharma, Inc. | Treprostinil derivative compounds and methods of using same |
| WO2014159050A1 (en) | 2013-03-14 | 2014-10-02 | United Therapeutics Corporation | Solid forms of treprostinil |
| BR112015023168B1 (pt) | 2013-03-15 | 2021-08-10 | Mannkind Corporation | Composição de 3,6-bis(n-fumaril-4-aminobutil)-2,5-dicetopiperazina cristalina, método de produção de partículas de 3,6-bis(n-fumaril-4-aminobutil)-2,5-dicetopiperazina e uso de uma composição de dicetopiperazina cristalina |
| ITMI20130572A1 (it) * | 2013-04-10 | 2014-10-11 | Eratech Srl | Composizione comprendente almeno due polveri secche ottenute per spray dry per aumentare la stabilita' della formulazione |
| CA2911172C (en) | 2013-04-30 | 2021-10-19 | United Therapeutics Corporation | Controlled release pharmaceutical formulations |
| US9349730B2 (en) | 2013-07-18 | 2016-05-24 | Globalfoundries Inc. | Fin transformation process and isolation structures facilitating different Fin isolation schemes |
| BR122019026637B1 (pt) * | 2013-07-18 | 2023-09-26 | Mannkind Corporation | Formulações farmacêuticas de pó seco e método para a fabricação de uma formulação de pó seco |
| ES2959419T3 (es) * | 2013-10-11 | 2024-02-26 | Pulmokine Inc | Formulaciones secas por aspersión |
| US9469600B2 (en) | 2013-10-25 | 2016-10-18 | Insmed Incorporated | Prostacyclin compounds, compositions and methods of use thereof |
| GB201400412D0 (en) * | 2014-01-10 | 2014-02-26 | Heart Biotech Ltd | Pharmaceutical formulations for the treatment of pulmonary arterial hypertension |
| MX2016010213A (es) | 2014-02-07 | 2017-04-13 | Auspex Pharmaceuticals Inc | Formulaciones farmaceuticas novedosas. |
| WO2015138423A1 (en) * | 2014-03-11 | 2015-09-17 | Insmed Incorporated | Prostacylin compositions and methods for using the same |
| CA2963085C (en) * | 2014-10-07 | 2023-02-21 | Lam Therapeutics, Inc. | An inhalable rapamycin formulation for the treatment of pulmonary hypertension |
| US9643911B2 (en) | 2015-06-17 | 2017-05-09 | Corsair Pharma, Inc. | Treprostinil derivatives and compositions and uses thereof |
| US9394227B1 (en) | 2015-06-17 | 2016-07-19 | Corsair Pharma, Inc. | Treprostinil derivatives and compositions and uses thereof |
| IL260823B2 (en) | 2016-01-29 | 2024-08-01 | Mannkind Corp | Dry powder inhaler |
| US20190321290A1 (en) | 2016-01-29 | 2019-10-24 | Mannkind Corporation | Composition and method for inhalation |
| EP3452170A4 (en) | 2016-05-05 | 2020-04-01 | Liquidia Technologies, Inc. | TREPROSTINIL IN POWDER FORM FOR TREATING PULMONAL HYPERTENSION |
| EP3554507A1 (en) | 2016-12-14 | 2019-10-23 | Respira Therapeutics, Inc. | Methods and compositions for treatment of pulmonary hypertension and other lung disorders |
| CA3102967A1 (en) | 2018-06-07 | 2019-12-12 | Mannkind Corporation | Composition and method for inhalation |
| CN112739679B (zh) | 2018-09-18 | 2024-03-12 | 伊莱利利公司 | 曲前列环素的特丁胺盐 |
| JP7365073B2 (ja) | 2019-05-21 | 2023-10-19 | ジァンスー フォアフロント ファーマシューティカル カンパニー,リミテッド | トレプロスチニルナトリウムの新規な結晶形および製造方法 |
| CN114401716A (zh) | 2019-07-22 | 2022-04-26 | 纳诺米有限公司 | 持续释放的曲前列环素-化合物微粒组合物 |
-
2017
- 2017-05-05 EP EP17793448.6A patent/EP3452170A4/en active Pending
- 2017-05-05 IL IL319790A patent/IL319790A/en unknown
- 2017-05-05 CA CA3023257A patent/CA3023257A1/en active Pending
- 2017-05-05 IL IL262720A patent/IL262720B2/en unknown
- 2017-05-05 JP JP2018558275A patent/JP2019519489A/ja active Pending
- 2017-05-05 WO PCT/US2017/031301 patent/WO2017192993A1/en not_active Ceased
- 2017-05-05 US US16/099,135 patent/US10898494B2/en active Active
- 2017-05-05 IL IL310250A patent/IL310250B2/en unknown
- 2017-05-05 AU AU2017261317A patent/AU2017261317A1/en not_active Abandoned
-
2020
- 2020-11-25 US US17/104,348 patent/US11712442B2/en active Active
-
2021
- 2021-07-30 US US17/390,514 patent/US11744836B2/en active Active
- 2021-07-30 US US17/390,476 patent/US11744835B2/en active Active
-
2022
- 2022-04-13 US US17/719,439 patent/US11660304B2/en active Active
-
2023
- 2023-03-01 JP JP2023031081A patent/JP2023071844A/ja active Pending
- 2023-03-02 AU AU2023201307A patent/AU2023201307A1/en not_active Abandoned
- 2023-07-12 US US18/350,926 patent/US12390475B2/en active Active
-
2025
- 2025-05-07 JP JP2025077118A patent/JP2025118785A/ja active Pending
- 2025-06-10 AU AU2025204321A patent/AU2025204321A1/en active Pending
- 2025-07-07 US US19/261,256 patent/US20250332175A1/en active Pending
-
2026
- 2026-03-26 US US19/629,817 patent/US20260216209A1/en active Pending
- 2026-03-26 US US19/629,870 patent/US20260216210A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018519818A5 (cg-RX-API-DMAC7.html) | ||
| ES2424476T3 (es) | Nanopartículas cargadas con fármaco antitumoral quimioterápico | |
| US20080066739A1 (en) | Methods and systems of delivering medication via inhalation | |
| RU2018113460A (ru) | Вдыхаемые никотиновые композиции и способы их получения и применения | |
| JP2011519932A5 (cg-RX-API-DMAC7.html) | ||
| JP2010505850A5 (cg-RX-API-DMAC7.html) | ||
| JP2012517987A5 (ja) | 吸入用の医薬組成物のfpd特性を設定する方法 | |
| WO2009112273A3 (en) | Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease | |
| JP2011105739A5 (cg-RX-API-DMAC7.html) | ||
| JP2015509788A5 (cg-RX-API-DMAC7.html) | ||
| FI3258919T4 (fi) | Nasaalinen jauheformulaatio hypoglykemian hoitoon | |
| HK1203149A1 (en) | Novel dosage form and formulation of abediterol | |
| UA101652C2 (uk) | Композиція для інгаляції, що містить аклідиній для лікування астми та хронічного обструктивного захворювання легень | |
| RU2018113272A (ru) | Никотиновые составы и способы их получения и применения | |
| JP2018527386A5 (cg-RX-API-DMAC7.html) | ||
| JP2016516751A5 (cg-RX-API-DMAC7.html) | ||
| EP3108882A3 (en) | Nanoparticle drug delivery | |
| CN116744939A (zh) | At-527半硫酸盐的有利形态 | |
| JP2021503483A5 (cg-RX-API-DMAC7.html) | ||
| JP2022527054A5 (cg-RX-API-DMAC7.html) | ||
| MX2020010977A (es) | Procedimientos de tratamiento de infecciones fúngicas. | |
| WO2017013542A1 (en) | Product based on iron bis-glycinate chelate and alginic acid and/or water-soluble salts thereof, formulations thereof, and pharmaceutical uses thereof | |
| TW202233167A (zh) | 血管疾病治療用組成物、血管疾病預防用組成物、高血壓治療用組成物,及高血壓預防用組成物 | |
| EP2821062A1 (en) | Novel dry powder inhaler formulations | |
| JP2015512923A5 (cg-RX-API-DMAC7.html) |